With Chinese firms becoming major players in drug development, the traditional balance of power in global pharmaceuticals is ...
Farallon presses Astellas to cut costs and overhaul drugs research in latest shareholder campaign gripping Tokyo ...
Gilead reports Q4 earnings on Feb. 11. Analysts expect $1.70 EPS. The LEO Pharma deal could reduce 2025 EPS by up to $0.17.
Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...
Private equity firm expects $3.3bn acquisition of Tanabe will get boost from eased approval process for new medicine ...
January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.
LEO Pharma and non-profit organisation DEBRA Research have announced a collaboration aimed at accelerating the development of treatments for epidermolysis bullosa (EB). The non-exclusive strategic ...
DEBRA Research and LEO Pharma enter strategic partnership to advance treatments for rare skin diseases: Munich, Germany Thursday, February 6, 2025, 10:00 Hrs [IST] DEBRA Research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback